Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Erivedge (vismodegib) is an oral hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery or radiation. Vismodegib works by selectively inhibiting the Smoothened (SMO) receptor, a key component of the hedgehog signaling pathway, which is abnormally activated in most cases of BCC. By targeting this pathway, Erivedge disrupts tumor cell proliferation and survival, offering a non-surgical option for difficult-to-treat or recurrent lesions.
Fact Table | |
Formula | C19H14Cl2N2O3S |
License | US FDA (2012) |
Bioavailability | At least 31.8% |
Legal status | Prescription only |
Chemical Name | Vismodegib |
Elimination half-life | 4 days (range: 12 hours–12 days) |
Dosage (Strength) | 150 mg oral capsules (once daily) |
Pregnancy | Contraindicated – causes fetal harm (Boxed Warning) |
Brands | Erivedge |
Protein binding | >99% |
PubChem CID | 24776412 |
MedlinePlus | a612014 |
ChEBI | 68531 |
ATC code | L01XX43 |
DrugBank | DB08816 |
KEGG | D09723 |
Routes of administration | Oral |
Erivedge is taken orally at a dose of 150 mg once daily, with or without food. Capsules must be swallowed whole and not opened, crushed, or chewed. Treatment should continue until disease progression or unacceptable toxicity. Patients should be monitored regularly for adverse effects, especially muscle spasms, weight loss, and laboratory abnormalities. Pregnancy status should be confirmed prior to initiation in females of reproductive potential due to the drug’s teratogenicity.
Each Erivedge capsule contains:
Erivedge is contraindicated in:
Erivedge is embryotoxic and teratogenic. It is subject to a Risk Evaluation and Mitigation Strategy (REMS) program to prevent fetal exposure. Both male and female patients must use effective contraception during treatment and for at least 3 (females) or 2 (males) months after the last dose. Use caution in patients with pre-existing muscle disorders due to the risk of rhabdomyolysis. Long-term use may cause premature closure of the epiphyses in pediatric patients. Safety and effectiveness in children have not been established.
Common and potential side effects include: